Biogen · 3 months ago
MBA 'IMPACT' Internship 2026
Biogen is a mid-sized biotechnology company committed to excellence and innovation in delivering life-changing medicines. The MBA 'IMPACT' Internship provides students with hands-on experience in the biotech industry, focusing on critical business projects across various teams including Marketing, Market Access & Reimbursement, and Business Intelligence and Operations.
BiotechnologyHealth CareNeuroscienceTherapeutics
Responsibilities
Assess competitive landscape and ensure readiness for key events
Supporting development of pricing and access strategies
Create framework to evaluate commercial viability of early stage or external assets
Develop marketing tools for use by Biogen’s affiliates
Assess opportunities to enhance product profile through life cycle management
Utilize data to create marketing mix models
Qualification
Required
Professional experience in life science, marketing, technology, or analytics preferred
Digital-savvy, strategic thinker with a passion for improving the patient and customer experience
Strong analytical and problem-solving skills
Established record of achievement and leadership
Strong oral and written communication skills, excellent interpersonal skills, and the ability to interact well with all levels of management
Process and results-oriented
Able to operate with agility and leverage emerging opportunities
Creative thinker who challenges the status quo
Bachelor's degree required
Enrolled in an accredited MBA Program with graduation planned for 2027
Permanent U.S. Work Authorization or be enrolled as a STEM MBA student
At least 18 years of age prior to the scheduled start date
Be currently enrolled in an accredited college or university
Preferred
If business school offers, concentration in marketing, general management, or healthcare management is preferred
Benefits
Company paid holidays
Commuter benefits
Employee Resource Groups participation
80 hours of sick time per calendar year
Company
Biogen
Biogen is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Funding
Current Stage
Public CompanyTotal Funding
$1.5BKey Investors
JP Morgan
2023-08-28Post Ipo Debt· $1.5B
1991-09-27IPO
Leadership Team
Recent News
Pharmaceutical Technology
2026-01-05
Company data provided by crunchbase